Decline in the use of anthracyclines for breast cancer

Journal of Clinical Oncology

Volumn 30, Issue 18, 2012, Pages 2232-2239

  Giordano, Sharon H ^a,b   Lin, Yu Li ^a,b   Kuo, Yong Fang ^a,b   Hortobagyi, Gabriel N ^a,b   Goodwin, James S ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; DOCETAXEL; EXEMESTANE; LETROZOLE; PACLITAXEL; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURGERY; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; DISEASE CLASSIFICATION; FEMALE; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MEDICARE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; BRIDGED COMPOUNDS; CHEMOTHERAPY, ADJUVANT; DRUG UTILIZATION; FEMALE; HUMANS; MIDDLE AGED; TAXOIDS;

EID: 84864000921     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.40.1273     Document Type: Article

References (20)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
2. Harlan LC, Clegg LX, Abrams J, et al: Community-based use of chemotherapy and hormonal therapy for early-stage breast cancer: 1987-2000. J Clin Oncol 24:872-877, 2006 (Pubitemid 46638838)
3. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684, 2005 (Pubitemid 41464706)
4. Pinder MC, Duan Z, Goodwin JS, et al: Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 25:3808-3815, 2007 (Pubitemid 47477254)
5. Piccart-Gebhart MJ, Burzykowski T, Buyse M, et al: Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol 26:1980-1986, 2008
6. Jones SE, Savin MA, Holmes FA, et al: Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 24:5381-5387, 2006 (Pubitemid 46623169)
7. Slamon DJ, Eiermann W, Robert N, et al: Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab in HER2 positive early breast cancer patients: BCIRG006 Study. Breast Cancer Res Treat 94:s5, 2005 (suppl)
8. Freeman JL, Zhang D, Freeman DH, et al: An approach to identifying incident breast cancer cases using Medicare claims data. J Clin Epidemiol 53:605-614, 2000 (Pubitemid 30394510)
9. Nattinger AB, Laud PW, Bajorunaite R, et al: An algorithm for the use of Medicare claims data to identify women with incident breast cancer. Health Serv Res 39:1733-1749, 2004 (Pubitemid 39601249)
10. Gold HT, Do HT: Evaluation of three algorithms to identify incident breast cancer in Medicare claims data. Health Serv Res 42:2056-2069, 2007 (Pubitemid 47397185)
11. Giordano SH, Duan Z, Kuo YF, et al: Impact of a scientific presentation on community treatment patterns for primary breast cancer. J Natl Cancer Inst 98:382-388, 2006
12. Jones SE, Savin MA, Holmes FA, et al: Final analysis: TC (docetaxel/cyclophosphamide, 4 cycles) has a superior disease-free survival compared to standard AC (doxorubicin/cyclophosphamide) in 1016 women with early stage breast cancer. Breast Cancer Res Treat 94:S20, 2005 (suppl)
13. Slamon D, Eiermann W, Robert N, et al: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273-1283, 2011
14. Henderson IC, Berry DA, Demetri GD, et al: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976-983, 2003 (Pubitemid 46594124)
15. Mamounas EP, Bryant J, Lembersky B, et al: Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28. J Clin Oncol 23:3686-3696, 2005
16. Burnell M, Levine MN, Chapman JA, et al: Cyclophosphamide, epirubicin, and fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node-positive or high-risk node-negative breast cancer. J Clin Oncol 28:77-82, 2010
17. Citron ML, Berry DA, Cirrincione C, et al: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431-1439, 2003 (Pubitemid 46594092)
18. Sparano JA, Wang M, Martino S, et al: Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358:1663-1671, 2008 (Pubitemid 351549913)
19. Siegel R, Ward E, Brawley O, et al: Cancer statistics: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61:212-236, 2011
20. Gnerlich J, Jeffe DB, Deshpande AD, et al: Surgical removal of the primary tumor increases overall survival in patients with metastatic breast cancer: Analysis of the 1988-2003 SEER data. Ann Surg Oncol 14:2187-2194, 2007 (Pubitemid 47174926)